Elena Ruiz de la Torre Gómez de Barreda. President of EHA

Slides:



Advertisements
Similar presentations
By Claudine HAMEL-DESNOS, Caen, France
Advertisements

Some issues raised by the implementation of integrated care for patients with chronic diseases National Implementation of Innovations in Integrated Care.
MEDICAL HOME 1/2009 Mary Goldman, D.O., President of MAOFP.
Migraine and Dizziness
How 2014 ACA Insurance Plans Cover Autism William Luvisi, President Senior Consultants Inc.
A Red Flags: 1. Progressively declining level of consciousness 2. Progressive declining neurological exam 3. Pupillary asymmetry 4. Seizures 5. Repeated.
2008. Diagnostic criteria  At least 10 episodes fulfilling following criteria  Headache lasting 30 mins to 7 days  Has 2 at least 2 of the following.
INTERNATIONAL CLASSIFICATION of HEADACHE DISORDERS 3rd edition beta, ICHD-3beta Jes Olesen, Danish Headach Center, Dept of Neurology, Glostrup Hospital,
Telehealth & Medicare Hospice Conditions of Participation Deborah Randall JD, Attorney/Telehealth Consultant,
Department of Neurology, SJUH Acute headache Problems that can not wait until the post take ward round
Edit the text with your own short phrases. To change the sample image, select the picture and delete it. Now click the Pictures icon in the placeholder.
Migraine JENNA GALLAGHER. What is a migraine?  A recurring throbbing headache that typically affects one side of the head and is often accompanied by.
跳转到第一页 Headache Zheng Dongming. 跳转到第一页 n The most common symptom in clinic n the causes are myriad. 1.intracranial disease 2.extracranial disease 3.functional.
Polypharmacy Among Older Adults in Tehran Tehran University of Medical Sciences, School of Public Health, Islamic Republic of Iran Ahmadi, Batoul, Pharm.
“My migraine always comes back” Presented by: Julio Pascual Neuroscience Area, Service of Neurology, University Hospital Central de Asturias and Ineuropa,
INTERNATIONAL MYELOMA FOUNDATION
Indianapolis Discovery Network for Dementia Comparative Effectiveness Research Trial of Alzheimer’s Disease Drugs: COMET-AD.
Therapeutic Education: Cancer Patients on chemotherapy: Shamim Akhter QURESHI MBBS,MPH, Ingénieur d’étude(EHESP) 2 nd June 2012 June 2010.
Migraine, help breaking the taboo P3BE Introduction Dr. Bart Vandersmissen Headache consultant, Department of Neurology Erasme Hospital, Brussels.
Introducing the Medication Recording System Schedule Ed Castagna Mom & Pop’s Small Business Services.
Recovery conceptualization and Treatment preferences: Choices for Clients with Psychosis in Northern Malawi By: Charles Masulani Mwale 1, 1 St John of.
Treating Chronic Pain in Adolescents Amanda Bye, PsyD, Behavioral Medicine Specialist Collaborative Family Healthcare Association 15 th Annual Conference.
Implementing the guidelines in Continuous Medical Education by the Audit méthod. Josiane ALBOUY (Regional Work Inspection for the « Région Centre »), Annie.
Occupational Health. Occupational Medicine Recognized Specialty Since 1949 Combines Clinical Skills With Toxicology, Epidemiology, Safety, Rehabilitation,
Swiss Re – Pandemic Risk Talk Ethical issues in palliative care for patients with M/XDR-TB Geneva, 19 November 2010 Palliative Care and M/XDR-TB meeting.
January is Glaucoma Awareness Month The information and recommendations appearing on these pages are informational only and is not intended to be a basis.
Exploitation Seminar , Budapest Presentation of European Family Set.
Towards a National Alliance against Chronic Respiratory Diseases Nikolai Khaltaev, MD, PhD March 2006, GARD General Meeting, Beijing, China.
How To Design a Clinical Trial
Learning Outcomes Discuss current trends and issues in health care and nursing. Describe the essential elements of quality and safety in nursing and their.
Dublin November 13 th 2011 By Dr. Edward O’Sullivan 13-Nov
SEMFYC: Spanish Society of Family and Community Medicine. Miguel García Ribes, José Vicente Sorlí Guerola. SEMFyC’s working group on Clinical Genetics.
Basic Concepts of Outcome-Informed Practice (OIP).
Canadian Best Practice Recommendations for Stroke Care Recommendation 1: Public Awareness and Patient Education (Updated 2008)
원더스 참고자료 두통. 1 차성 두통에 대한 자료 2 차성 두통에 대한 자료.
Migraine, reducing a negative aura. Introduction Marc-Henry Cornély Ophaco.
Survey of Respiratory Diagnostic Laboratories to Inform the National COPD Strategy T McCarthy,* A McGowan, ¥ M O’Connor,* on behalf of the National COPD.
Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur.
SOONERCARE PAIN MANAGEMENT PROGRAM. SOONERCARE PAIN MANAGEMENT PROGRAM The SoonerCare Pain Management Program is designed to equip SoonerCare providers.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
Documentation.
Program overview Special arrangement with Cleveland Clinic for access to electronic second opinions through their MyConsult Online Medical Second Opinion.
EUNetPaS European Union Network for Patient Safety
Medical Assistance in Dying
Drugs for Migraine
Antibiotics: handle with care!
prof elham aljammas APRIL2017
How To Design a Clinical Trial
MEDICS CATALONIA PROJECT
NeurOn: Modeling Ontology for Neurosurgery
Palliative Approach to Care
Enrolling in Clinical Trials
Dr Mohamad Shehadeh Agha MD MRCP(UK)
Headache.
C-SCOPE: Survey on the Management of HCV in addiction clinics treating Patients on Opiate Agonist Therapies: a global perspective July 2017.
Phase 4 Milestones.
Migraine - an overlooked neurological disorder
The Community as a Client: Assessment and Diagnosis
Dr. Muhammad Ajmal Zahid Chairman, Department of Psychiatry,
The HIPAA Privacy Rule and Research
INTERNATIONAL CLASSIFICATION of HEADACHE DISORDERS 3rd edition beta, ICHD-3beta Jes Olesen, Danish Headach Center, Dept of Neurology, Glostrup Hospital,
The Health Insurance Portability and Accountability Act
Concepts of Nursing NUR 212
Steering Group Meeting
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
Diagnosis of disease M2/D2
INTERNATIONAL CLASSIFICATION of HEADACHE DISORDERS 3rd edition beta, ICHD-3beta Jes Olesen, Danish Headach Center, Dept of Neurology, Glostrup Hospital,
Dr sadik al ghazawi Associated professer Neurologist Mrcp,frcp uk
Introduction to Clinical Pharmacology Chapter 4 The Nursing Process
Dr sadik al ghazawi Associated professer Neurologist Mrcp,frcp uk
Presentation transcript:

Elena Ruiz de la Torre Gómez de Barreda. President of EHA MIGRAINE AND WORK A COMPLETE VISION OF THE WORKER WITH MIGRAINE IN THE SOCIO- LABOR FIELD Elena Ruiz de la Torre Gómez de Barreda. President of EHA María Teresa Bernal García. Member of the Spanish Association of Specialists in Occupational Medicine (AEEMT)

What factors show more relation with the aftermath of the disease What is the start point? What factors show more relation with the aftermath of the disease How can we act to improve? 3-Design interventions based on data obtained 1-Survey data 2-Results of the statistical study

EUROPEAN MIGRAINE AND WORK STUDY Design of this study: Research Group in Occupational Medicine, with the scientific endorsement of the Spanish Association of Specialists in Occupational Medicine (AEEMT). The intellectual property of this work corresponds to EHA, represented by their president, Ms. Elena Ruiz de la Torre

EUROPEAN MIGRAINE AND WORK STUDY Participating countries: Spain, Ireland, England, Italy, Germany and France Data on common basis: on the EHA server Priority language: English with choice options (Spanish, French, Italian and German) Channel the project in each country through societies or associations of occupational physicians or occupational nurses All the participating authors will be included in the subsequent project dissemination documents

Person who works and suffers migraine PERSONAL AND FAMILY CIRCUMSTANCES CLINICAL AND CARING SITUATION WORKING AND SOCIAL SITUATION Person who works and suffers migraine

OBJECTIVES OF THE STUDY To know the situation of the worker with migraine within the companies, their personal, social and clinical-assistance conditions Starting point for subsequent improvement initiatives, implementation of preventive measures and maximum integration of migraine workers within companies Facilitate the maximum benefit in subsequent interventions for: Working affected people For health caregivers who perform their control and follow-up For the companies For society Results will make possible to compare results among countries and apply subsequent protocols based on each countries’ regulations for the prevention of occupational risks.

EUROPEAN MIGRAINE AND WORK STUDY Start planned: Pilot Project in Spain in April 2018 Global start rest countries May 2018 Completion of data collection: November 2018 Sample size for each participating country: Minimum of 500 workers for each country Desirable objective 1000 workers for each country

EUROPEAN MIGRAINE AND WORK STUDY Previous materials: Informed consent Medical training material. Power point with diagnostic criteria of the pathology Patient brochure (migraine and work) Questionnaire (approximate data collection time 6 min): In paper format : Word / pdf if there is no Internet access. Later it has to be turned to the electronic format In electronic format through the EHA website: link- https: //it.surveymonkey.com/r/77TGQBK Contact for questions : mail available in the corresponding country https://it.surveymonkey.com/r/77TGQBK

EUROPEAN MIGRAINE AND WORK STUDY Subsequent statistical treatment by an expert centralized in Spain: descriptive, bivariate and multivariate Diffusion Global study publications Individualized for each country Presentation of results in appropriate national and international forums

5- Dissemination and presentation of the project 1-Prepare materials and contact societies and associations at each country 2- Once the project has been accepted, collect the number of participating occupational physicians / nurses 3- Collection of data from April-November 2018 (minimum 500 per country, optimum 1000 per participating country) 4- Perform statistical study and analysis of the results obtained and prepare the results documents / publications 5- Dissemination and presentation of the project

EUROPEAN MIGRAINE AND WORK STUDY CRITERIA OF INCLUSION OF THE WORKER IN THE STUDY: Voluntary participation With informed consent (for epidemiological use of the data) – SEE ATTACHMENT Compliance with migraine criteria-SEE ANNEX (for the doctor) To be working at the time of the survey, or have been employed in the previous year

EUROPEAN MIGRAINE AND WORK STUDY DIAGNOSTIC CRITERIA: Migraine without aura A. At least 5 attacks that meet B-D criteria B. Headache that lasts from 4 to 72 hours (without treatment or insufficiently treated) C. Headache that meets two of the following characteristics: One-sided location Pulsatile characteristic From moderate to severe intensity of pain Worsened by or causing avoidance of habitual physical activity (e.g., walking or climbing stairs) D. During the headache, one of the following occurs: Nausea and / or vomiting Photophobia or phonophobia. E. Not attributed to another disease

EUROPEAN MIGRAINE AND WORK STUDY DIAGNOSTIC CRITERIA: Migraine with aura A. At least 2 attacks that meet criterion B B. Migraine with aura that meet the B-C criteria for any of the subforms (migraine with typical aura, non-migraine headache with typical aura, headache without typical aura, familial hemiplegic migraine, sporadic hemiplegic migraine, or basilar-type migraine) C. Not attributed to another disease

EUROPEAN MIGRAINE AND WORK STUDY DIAGNOSTIC CRITERIA: Migraine with typical aura A. At least 2 attacks that meet B-D criteria B. Aura consisting of at least one of the following symptoms, but not motor weakness: Fully reversible visual symptoms including positive features (eg, light flashes, scotomas or lines) and / or negative features (loss of vision) Fully reversible sensory symptoms including positive features (pins and needles) and / or negative features (numbness) Fully reversible alterations of dysphasic language C. At least 2 of the following: Visual homonymous symptoms and / or unilateral sensory symptoms At least one of the symptoms of the aura develops gradually from> / = 5 minutes and / or different aura symptoms occur in succession of > / = 5 minutes Each symptom lasts > / = 5 and </ = 60 minutes D. The headache meets the B-D criteria for "Migraine without aura" beginning during the aura or followed by the aura within 60 minutes E. Not attributed to another disease

EUROPEAN MIGRAINE AND WORK STUDY DIAGNOSTIC CRITERIA: Migraine without typical aura As the "Migraine with typical aura", except: B. Aura consisting of at least one of the following, with or without speech alterations but without motor weakness: Fully reversible visual symptoms including positive features (eg, light flashes, scotomas or lines) and / or negative features (loss of vision) Fully reversible sensory symptoms including positive features (pins and needles) and / or negative features (numbness) C. Headache that does not occur during the aura or followed by the aura within 60 minutes

EUROPEAN MIGRAINE AND WORK STUDY DIAGNOSTIC CRITERIA: Chronic migraine Description: Headache that appears for 15 days or more per month for more than three months, and that, at least for 8 days a month, has characteristics of migraine headache . Diagnostic criteria A. Headache (tensional or migrainous type) during a period of 15 or more days per month for more than 3 months2 that meets criteria B and C. B. It appears in a patient who has suffered at least five seizures that meet the B-D criteria for 1.1 Migraine without aura and / or criteria B and C of 1.2 Migraine with aura. C. During a period of 8 or more days per month for a period of more than 3 months, it meets any of the following: 1. Criteria C and D for the 1.1 Migraine without aura. 2. Criteria B and C for 1.2 Migraine with aura. 3. At the time of appearance, the patient believes that it is migraine, and is relieved with a triptan or ergot derivatives. D. Without better explanation for another diagnosis of ICHD-III.

EUROPEAN MIGRAINE AND WORK STUDY

Electronic access - link to the survey QUESTIONNAIRE Electronic access - link to the survey personal information migraine data labor data data of the medical professional / nurse who collects the survey https://it.surveymonkey.com/r/77TGQBK

Helpdesk and consultants: English: Andrea Rodríguez German: Maria-Teresa Bernal Italian: Patrick Cadeddu French: Maria-Jesus Terradillos Global Coordination: Mª Teofila Vicente and the Goup od Research in Occupational Medicine With the scientific support of the Spanish Association of Specialists in Occupational Medicine Contact: info@europeanheadachealliance.org. From this address the question will be redirected to the person in the country the request comes from.

THANK YOU FOR YOUR COOPERATION